Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q2 EPS of ($0.36), $0.08 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $114 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Constellation Brands (STZ) Tops Q1 EPS by 18c
• Horizon Bancorp faces $3M jury verdict in auto repossession case